[ ]
Международное непатентованное наименование BLD-2660
Торговое наименование -
Производитель, страна Blade Therapeutics, USA
Механизм действия

BLD-2660, synthetic small-molecule inhibitor of calpain. Calpains are a class of non-lysosomal cysteine proteases involved in diverse cellular processes. Several publications indicate that specific host calpains are essential for the replication of multiple RNA viruses including Coronaviruses. BLD-2660 has also been shown to normalize interleukin (IL)-6, a pro-inflammatory cytokine demonstrated to be elevated in COVID-19 patients and is implicated in disease pathogenesis.

Публикации COVID-19

FNU ShwetaKarthik Murugadoss, et al. Augmented Curation of Unstructured Clinical Notes from a Massive EHR System Reveals Specific Phenotypic Signature of Impending COVID-19 Diagnosis. April 30, 2020. DOI: 10.1101/2020.04.19.20067660. 

Клинические исследования
Название протокола Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment
Дата начала и окончания КИ May 4, 2020 - September 2020
Название организации, проводящей КИ Blade Therapeutics
Страны USA
Фаза II
Кол-во пациентов 120